

Background

Despite the high cure rates achieved with currently available direct-acting antiviral HCV therapy, treatment failure can occur in as many as 10% of individuals – often associated with the development of resistance associated substitutions (RASs). Little is known about the real-world efficacy of currently available salvage options, particularly among vulnerable populations such as PWID. The aim of this analysis was to evaluate the efficacy of sofosbuvir/velpatasvir/voxipalrevir (SVV) and glecaprevir/pibrentavir + sofosbuvir (GPS) as retreatment strategies among HCV-infected PWID.

Methods

A retrospective analysis was performed among all HCV-infected PWID who were initiated on salvage therapy at our centre between 06/17-04/19, excluding cases of re-infection. The presence of RASs was determined by sequencing prior to HCV re-treatment. All subjects were enrolled in a multidisciplinary model of care, addressing medical, psychologic, social and addiction-related needs. The primary outcome was SVR12 (undetectable HCV RNA 12 weeks after the end of treatment).

Results

A total of 13 individuals were included in this analysis, mean age 56 years, 77% male, 77% Caucasian, 62% homeless, 54% actively using drugs during treatment (75% opiates, 50% amphetamines) and 46% on opiate substitution therapy. Virologic characteristics include 46% GT1a, 31% GT3a, 8/10 patients with available data demonstrating RASs conferring NS5A and/or NS3 resistance. The outcome of initial therapy was true virologic relapse (n = 10) or non-response (n = 3); 11 patients received SVV while 2 received GPS. SVR12 was documented in all 13 patients.

Table 1. Patient Demographics

Parameter	Value [n=13]
Mean Age (years)	56
Male	10 (77%)
Caucasian	10 (77%)
Homeless	8 (62%)
Active drug use	7 (54%)
Opiate substitution	5 (46%)
Treatment experienced	13 (100%)

Table 2. Drug Use Data

Parameter	Value [n=13]
Active Drug use	7 (54%)
Past (non-active) drug use	6 (46%)
Cocaine only	10 (77%)
Amphetamines only	8 (62%)
Opiated only	7 (58%)
Multi-drug use	5 (46%)

Fig 1. Resistance Data




Table 3. Treatment Data

Parameter	Value [n=13]
Genotype	
• 1a	6 (46%)
• 2a/ac	2 (15%)
• 3a	4 (30%)
• 4	1 (8%)
sofosbuvir/velpatasvir/voxipalrevir	11 (85%)
glecaprevir/pibrentavir + sofosbuvir	2 (15%)
SVR-12	13 (100%)

Conclusion

Even with highly effective regimens for the treatment of HCV infection, some patients still fail initial therapy and require re-treatment. This may prove challenging, especially among PWID. We have demonstrated that even in this challenging population, the administration of salvage therapy with either SVV or GPS in the context of a multidisciplinary model of engagement in care is highly successful. These data provide further support for initiation of HCV therapy in PWID, even among individuals having failed first line DAA therapy.